Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Varuni Kondagunta

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumorsG Varuni Kondagunta, Jennifer Bacik, Dean Bajorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumorsG Varuni Kondagunta, Jennifer Bacik, Alessia Donadio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Phase II trial of bortezomib for patients with advanced renal cell carcinomaG Varuni Kondagunta, Beverly Drucker, Lawrence Schwartz, et al.
Investigational New Drugs|December 28, 2007
Phase II trial of lenalidomide in patients with metastatic renal cell carcinomaPremal H Patel, G Varuni Kondagunta, Lawrence Schwartz, et al.
Cancer|November 4, 2006
Treatment outcome for metastatic papillary renal cell carcinoma patientsEllen A Ronnen, G Varuni Kondagunta, Nicole Ishill, et al.
Clinical Genitourinary Cancer|May 27, 2008
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinomaDarren R Feldman, G Varuni Kondagunta, Lawrence Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapyG Varuni Kondagunta, Joel Sheinfeld, Madhu Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Clinical outcome and predictors of survival in late relapse of germ cell tumorDavid S Sharp, Brett S Carver, Scott E Eggener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapyEllen A Ronnen, G Varuni Kondagunta, Jennifer Bacik, et al.
Investigational New Drugs|July 13, 2006
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinomaEllen A Ronnen, G Varuni Kondagunta, Nicole Ishill, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumorsG Varuni Kondagunta, Jennifer Bacik, Dean Bajorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumorsG Varuni Kondagunta, Jennifer Bacik, Alessia Donadio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Phase II trial of bortezomib for patients with advanced renal cell carcinomaG Varuni Kondagunta, Beverly Drucker, Lawrence Schwartz, et al.
Investigational New Drugs|December 28, 2007
Phase II trial of lenalidomide in patients with metastatic renal cell carcinomaPremal H Patel, G Varuni Kondagunta, Lawrence Schwartz, et al.
Cancer|November 4, 2006
Treatment outcome for metastatic papillary renal cell carcinoma patientsEllen A Ronnen, G Varuni Kondagunta, Nicole Ishill, et al.
Clinical Genitourinary Cancer|May 27, 2008
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinomaDarren R Feldman, G Varuni Kondagunta, Lawrence Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapyG Varuni Kondagunta, Joel Sheinfeld, Madhu Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Clinical outcome and predictors of survival in late relapse of germ cell tumorDavid S Sharp, Brett S Carver, Scott E Eggener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapyEllen A Ronnen, G Varuni Kondagunta, Jennifer Bacik, et al.
Investigational New Drugs|July 13, 2006
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinomaEllen A Ronnen, G Varuni Kondagunta, Nicole Ishill, et al.
Pageof 3